Analysts Set Liquidia Co. (NASDAQ:LQDA) Price Target at $25.38

Shares of Liquidia Co. (NASDAQ:LQDA - Get Free Report) have received an average recommendation of "Buy" from the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $25.38.

LQDA has been the topic of several analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $19.00 price target on shares of Liquidia in a research report on Thursday. Scotiabank started coverage on Liquidia in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $30.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and issued a $29.00 target price on shares of Liquidia in a research note on Thursday, November 14th. Lifesci Capital assumed coverage on shares of Liquidia in a research report on Thursday, October 3rd. They set an "outperform" rating and a $30.00 price target on the stock. Finally, Wells Fargo & Company assumed coverage on shares of Liquidia in a research report on Friday, December 20th. They issued an "overweight" rating and a $20.00 price objective for the company.

Liquidia Trading Down 2.2 %

Shares of LQDA stock traded down $0.27 during trading hours on Friday, hitting $12.19. The company's stock had a trading volume of 594,022 shares, compared to its average volume of 746,220. The company has a 50 day moving average of $11.15 and a 200 day moving average of $11.04. Liquidia has a 12-month low of $8.26 and a 12-month high of $16.99. The stock has a market cap of $1.03 billion, a PE ratio of -7.48 and a beta of 0.23.

Insider Activity

In related news, insider Rajeev Saggar sold 2,260 shares of the business's stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $25,108.60. Following the transaction, the insider now directly owns 207,383 shares in the company, valued at approximately $2,304,025.13. The trade was a 1.08 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Michael Kaseta sold 3,892 shares of the company's stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $43,240.12. Following the sale, the chief financial officer now directly owns 311,076 shares of the company's stock, valued at approximately $3,456,054.36. This represents a 1.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,007 shares of company stock worth $245,780 over the last 90 days. 30.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Liquidia

A number of institutional investors have recently added to or reduced their stakes in LQDA. Whitcomb & Hess Inc. grew its stake in shares of Liquidia by 10.2% in the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company's stock valued at $116,000 after buying an additional 1,074 shares during the period. Arizona State Retirement System grew its position in Liquidia by 10.7% in the second quarter. Arizona State Retirement System now owns 13,842 shares of the company's stock worth $166,000 after acquiring an additional 1,341 shares during the period. Quest Partners LLC acquired a new stake in Liquidia during the second quarter worth $27,000. Profund Advisors LLC raised its position in Liquidia by 31.6% in the second quarter. Profund Advisors LLC now owns 14,434 shares of the company's stock valued at $173,000 after purchasing an additional 3,466 shares during the period. Finally, DMC Group LLC lifted its stake in shares of Liquidia by 36.7% in the 3rd quarter. DMC Group LLC now owns 13,883 shares of the company's stock valued at $139,000 after purchasing an additional 3,725 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company's stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).